{"name":"AeroRx Therapeutics Inc.","slug":"aerorx-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AERO-001","genericName":"AERO-001","slug":"aero-001","indication":"Other","status":"phase_1"},{"name":"AERO-002","genericName":"AERO-002","slug":"aero-002","indication":"Other","status":"phase_1"},{"name":"AERO-007","genericName":"AERO-007","slug":"aero-007","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AERO-001","genericName":"AERO-001","slug":"aero-001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AERO-002","genericName":"AERO-002","slug":"aero-002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AERO-007","genericName":"AERO-007","slug":"aero-007","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQUmhJZm41aTB5dC1PamJBRVZKSjZ3QnpyRm9pb1d6SzE3blBBM1REQWZMMVltVXpaaF9rMTRkRzJOWENwdENhUjNXa3RHcnV2Mm05NXgzTE9NemthblQzMWRzQ1VWdmRkenV1XzFIWnBBdVdWVHAtUUVjenBQYUpGWFhR?oc=5","date":"2025-11-03","type":"pipeline","source":"San Diego Business Journal","summary":"AeroRx Nets $21M Series A - San Diego Business Journal","headline":"AeroRx Nets $21M Series A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPbVU3VTdEbmRPWHhKS2hpRmFZRjU5eXFGNXhUdUc5SU51aWR0ZzJXeVpCbDRNaUdSeWN6ZnY2bTB2M0doMUkzUmRKQkFzRi1GRW51cGdXdTlkdmFuTkdsUWtNM3BITXNCZklCdTZ4Z3ZETkZueUNheFhrNGlWN0wyeEpqZWozZnduWmpXcUU3VXllYmlpNTlxT1Vn?oc=5","date":"2025-10-09","type":"pipeline","source":"WSJ","summary":"VCs Pour Capital Into Search for Lung Disease Treatments - WSJ","headline":"VCs Pour Capital Into Search for Lung Disease Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOeFNSeDJKNUI2V0xNb2psVUZNckpuV0JmcGVuZ0VDV3hjcTJXRTRxbUpVRm1JMDl2c05wWVY1Z0VPTWIzUVZKT2Jjd091eml3WXBLaVFRRkV0cWxQY2hKalAwbnRvV2h1dnRaVXQ0aTRMczcyREQ0c0p4S1JHS1hEc1dTRVd0cEJZVFhadHVWUHZwaUJkb2h1cW5OZ0xfSE5GUzVLTlk2bHRPNU9LbElMRlVOV3JvemU5SmNTMktvMGk4NkdzRTFqQm5GazBJVllWa2ZsLXNyOXdRVGQwX0hpQjRnLWxYM0poSWE5MTFzZFI4SGhmb04zRlVBUndOZy1HOTh5VjVXWVFQeE9fRENyTWN5X0FqbWg4S01BQW5CbUp1MTdCUjRfdGVqSUZ1aDJBcVJ5cGNxQUJNM25pd25oZDZURjE?oc=5","date":"2025-10-07","type":"pipeline","source":"businesswire.com","summary":"AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical Development - businesswire.com","headline":"AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5UeVkzTm9wVTZtaklWUDFmLVEzQTIyY3ctdkh2YXctRXJrUk1qT0FhTnlqaHJwN1JDY2JNS3NUVXJYT1NzYWlxQU5NUWN1VDVldmdJ?oc=5","date":"2025-10-07","type":"trial","source":"FirstWord Pharma","summary":"AeroRx raises $21M for mid-stage study of nebulised COPD treatment - FirstWord Pharma","headline":"AeroRx raises $21M for mid-stage study of nebulised COPD treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNOE5ZWExHOG12WHVHbE51TGRmcllseE1IZXVwME5aaURsaGRxaFdqamN6cEhHdVl2TkhobHZqQnlnYldiWXFCcEE2SUZiX2RxREE1OWFrR05aaEFUY1hGNFJCNmk3NU9QVkpMM05PT2J1UlFQMlJJVjVwQ1VKZThVTVFGYjlCZw?oc=5","date":"2025-08-19","type":"pipeline","source":"Pharmaceutical Executive","summary":"Creating Momentum for COPD Treatments: Q&A with Dr. Ahmet Tutuncu - Pharmaceutical Executive","headline":"Creating Momentum for COPD Treatments: Q&A with Dr. Ahmet Tutuncu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTk9La3ZZV0VCZ0Z4REhuX2c4anFGQ3k1cUJERzVaS0QzSGhwZTVaSGg2OVJmVUVDZ0NpdFhOQmszRjdhaVJ2dHZlbEZhU1hucWQ1SHJzbVN6UzdhdzRsU1JNVjhQY29VYTFEZG9qTmNrZmQtS2U2UW5hRGFZNHoxVEFsU1M1YlB0QTZiQ1BpeEhDclk4UG5xeEtYZXk2Q0JZdU5lN2tZcEpMNTVuUmpFZkY0eGo?oc=5","date":"2025-08-13","type":"pipeline","source":"San Diego Business Journal","summary":"AeroRx ‘Full Speed Ahead’ on Developing Nebulized COPD Treatment - San Diego Business Journal","headline":"AeroRx ‘Full Speed Ahead’ on Developing Nebulized COPD Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOOUJCMHZtMWJ1eE5Jck1teWhyb3E2TzJXNllfLUJ0cWJ2YUlOdnJkMkxZcTZIcUZ4MUpSX2JoU2tWOFhCWF9aU05aTjVHc2VrLTdSazNjN2k4NXl3WG5yOThhc3RrdnBxa0hFXzN3U2FpLUVCQlBicjVUalNIS2FJUElIOEhVb3M2QzFlSm5pU1lFYUFUckt1OEFKX0tZN2ZnaTFPNXh1cktpZ1hxbmh2dlJ6VjBkV21LYVlfdVpHSnVrTG02THZNUXNWQlpCdnVBaGRyakgxakZSMXlwVFpMb29ieGYxOW9xN2NpdFhsbHJHRE5kc0otWHBrd0pUTWpTeF9vYzdwVDZjamlLS3Bnd1RCdndRUQ?oc=5","date":"2025-07-30","type":"trial","source":"BioSpace","summary":"AeroRx Therapeutics Announces Topline Positive Phase 2a Data for Inhaled AERO-007, the First Nebulized LABA/LAMA Combination in Development for COPD - BioSpace","headline":"AeroRx Therapeutics Announces Topline Positive Phase 2a Data for Inhaled AERO-007, the First Nebulized LABA/LAMA Combina","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE4zYXdQMnBwUDFzdlQ0LWNLWkJaWWZobFhQdi1RakE2Q0FWdC1uTVo1ZERjYWF3aXdIU2FUdENRM1hwMWQwX3ZMZzhBTjFfOEpaYkFYRlRuQXA1NERRN2xGNkw5d3ROZ0VEeDZlRlc0bm5RUEt6?oc=5","date":"2023-05-11","type":"pipeline","source":"Straits Research","summary":"Aerosol Delivery Devices Market Size, Share & Growth Graph by 2034 - Straits Research","headline":"Aerosol Delivery Devices Market Size, Share & Growth Graph by 2034","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}